Brief: Clarity Pharmaceuticals Announces Acquisition Of Targeted Nanobody Platform
31/05/2022 02:31
May 31 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* ACQUISITION OF A TARGETED NANOBODY PLATFORM TO ITS
DISCOVERY
PIPELINE
Source text for Eikon: ID:nASXbTYKFV
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial